BAVARIAN NORDIC (OTCMKTS:BVNRY) released its quarterly earnings results on Friday. The company reported $0.07 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.14 by $0.07, reports. The company had revenue of $58.68 million during the quarter, compared to the consensus estimate of $50.65 million. BAVARIAN NORDIC had a return on equity of 7.82% and a net margin of 12.95%.

Shares of BAVARIAN NORDIC (OTCMKTS:BVNRY) opened at 21.6006 on Friday. BAVARIAN NORDIC has a 52 week low of $10.56 and a 52 week high of $17.33. The stock has a market cap of $2.04 billion and a P/E ratio of 83.5911. The stock has a 50 day moving average price of $11.70 and a 200-day moving average price of $11.70.

COPYRIGHT VIOLATION WARNING: This article was posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at

Separately, Zacks Investment Research downgraded BAVARIAN NORDIC from a “buy” rating to a “hold” rating in a research note on Tuesday, May 16th.


Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of novel vaccines for the prevention and treatment of life-threatening infectious diseases and cancer. The company markets non-replicating smallpox vaccine under the IMVAMUN and IMVANE names. It is also developing MVA-BN Filo that is in Phase III trial for the treatment of Ebola and Marburg; MVA-BN RSV, which is in Phase II clinical development stage for the prevention of respiratory syncytial virus; and MVA-BN HPV that is in preclinical development stage to treat human papillomavirus.

Receive News & Ratings for BAVARIAN NORDIC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BAVARIAN NORDIC and related companies with Analyst Ratings Network's FREE daily email newsletter.